期刊文献+

普芦卡必利关键中间体4-氨基-5-氯-2,3-二氢-7-苯并呋喃苯甲酸的合成工艺研究 被引量:1

Synthesis of 4- Amino- 5- Chloro- 2,3- Dihydrobenzofuran- 7- Carboxylic Acid,a Prucalopride's Synthetic Intermediate
下载PDF
导出
摘要 目的研究普芦卡必利关键中间体4-氨基-5-氯-2,3-二氢-7-苯并呋喃苯甲酸的合成工艺。方法以2-甲氧基-4-乙酰氨基-5-氯苯甲酸甲酯为起始原料,经脱甲基、溴化、缩合、环合、水解得到目标产物。结果经五步合成了目标产物,总收率为63%,目标化合物结构经1HNMR和MS确证。结论该合成方法原料易得,反应条件温和,适合大规模制备。 Objective To study the synthetic process of 4- Amino- 5- chloro- 2,3- dihydrobenzofuran- 7- carboxylic acid,the key intermediate for the preparation of prucalopride.M ethods The target compound was prepared through demethylation,bromination,condensation,cyclization and hydrolysis reaction with 2- methoxy- 4- acetylamino- 5- chloro methyl benzoate as starting material.Results The target compound was obtained through a 5- step procedure in an overall yield of 63%.The structure of target compound was confirmed by ~1HNMR and MS.Conclusion The easy availability of the reactants,facile reaction conditions and convenient operation procedures make the process a promising prospect for application in large- scale manufacture.
出处 《中国药业》 CAS 2016年第2期38-40,共3页 China Pharmaceuticals
关键词 普芦卡必利 4-氨基-5-氯-2 3-二氢-7-苯并呋喃苯甲酸 合成 prucalopride 4-Amino-5-chloro-2 3-dihydrobenzofuran-7-carboxylic acid synthesis
  • 引文网络
  • 相关文献

参考文献6

  • 1宁卉,赵志刚.治疗慢性便秘的新型促动力药普芦卡必利[J].药品评价,2013,10(12):18-21. 被引量:15
  • 2帅晓玮,王蔚虹.普芦卡必利对慢性便秘的治疗作用[J].临床药物治疗杂志,2014,12(6):46-49. 被引量:15
  • 3Daele G. N - (3 - hydroxy - 4 - piperidinyl) (dihydrobenzo furan, dihydro - 2H - benzopyran or dihydrobenzodioxin) carboxamide derivatives : US5374637 [P]. 1994 - 12 - 20.
  • 4Takuji. Synthesis and structure - activity relationship of 3 - sub- stituted benzamide, benzofuran - 7 - eaboxamide, 2, 3 - dihy- drobenzofuran - 7 - carboxamide, and indole - 5 - carboxamide derivatives as selective serotonin 5- HT4 receptor agonists[J] . Chemical and Pharmaceutical Bulletin, 1998,46 (1):42 -52.
  • 5Terricabras B. N - amide derivatives of 8 - azabicyclo[3, 2, 1 ] oct - 3 - yl as ccrl antagonists: WO2006133802[P] . 2006 - 05 - 30.
  • 6Willemsens B, Copmans A, Beerens D, et al. Dihydro - 7 - benzo- furancarboxylic acid: An intermediate in the synthesis of the en- teroldnetic agent R108512[M]. Washington: American Chemical Society ,2003 : 125 - 139.

二级参考文献36

  • 1Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride(R093877) on colonic motility in fasted dogs[J]. Neurogastroenterol Motil,2001,13(5):465-472.
  • 2Schuurkes JAJ, Van Nueten JM, Van Daele PGH, et al. Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig[J]. Pharmacol Exp Ther,1985,234:775-783.
  • 3Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo[J].J Pharmacol Exp Ther, 1997,280(3):1270-1276.
  • 4Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation[J]. N Engl J Med, 2008, 358(22):2344-2354.
  • 5Tack J, van Outryve M, Beyens G, et al. Prucalopride(Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives[J]. Gut, 2009,58(3):357-365.
  • 6Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constlpation--a 12-week, randomized, double-blind, placebo-controlled study[J]. Aliment Pharmacol Ther,2009,29(3):315-328.
  • 7Camilleri M , Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies[J]. Aliment Pharmacol Ther ,2010,32(9): 1113-1123.
  • 8Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study[J]. Neurogastroenterol Motil,2012,24(11 ):999-e541.
  • 9FDA.Propulsid (cisapride) Dear Healthcare Professional Letter. Fda website, http://www.fda.gov/Safety/MedWatch/SafetyIn formation/ SafetyAlerts forHumenMedicalProducts/ucm 175000.htm.2000-04- 12/2013-03-25.
  • 10Pau D, Workman AJ, Kane KA, et al. Electrophysiological effects of prucalopride,a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists[J]. J Pharmacol Exp Ther,2005,313(1 ): 146-153.

共引文献24

同被引文献4

引证文献1

;
使用帮助 返回顶部